Page last updated: 2024-08-25

lotrafiban and Cerebral Arteriosclerosis

lotrafiban has been researched along with Cerebral Arteriosclerosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Armstrong, PW; Califf, RM; Card, T; Chan, R; Graffagnino, C; Granett, J; Harrington, RA; Joseph, DM; Kereiakes, DJ; Samuels, R; Sigmon, KN; Topol, EJ; Van De Werf, F	1

Trials

1 trial(s) available for lotrafiban and Cerebral Arteriosclerosis

Article	Year
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation, 2000, Aug-15, Volume: 102, Issue:7 Topics: Administration, Oral; Aged; Benzodiazepines; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Treatment Outcome	2000

Article

Year

Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.

Circulation, 2000, Aug-15, Volume: 102, Issue:7

Topics: Administration, Oral; Aged; Benzodiazepines; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Treatment Outcome

2000